2013年9月3日讯 --诺和诺德（Novo Nordisk）9月2日宣布，在印度推出注射胰岛素Tresiba，该药用于糖尿病患者的治疗。

Tresiba是胰岛素degludec的商品名，这是一种新一代每日一次的超长效基础胰岛素类似物，作用持续时间超过42小时，赋予了日常服药时间的灵活性，同时不影响疗效和低血糖风险。

Tresiba将以一种预装胰岛素笔形式上市，该胰岛素笔配有一个简便的触摸按钮，单次注射可提供高达80单位的剂量。

诺和诺德已在一项大型临床试验项目BEGIN中，从血糖控制、低血糖事件等方面对Tresiba进行了评估。研究数据表明，Tresiba显着降低了全天及夜间低血糖风险，并成功实现了糖化血红蛋白（HbA）水平的降低。

目前，诺和诺德在印度糖尿病护理市场中的份额为15%。

英文原文：Novo Nordisk to launch insulin injection Tresiba in India

MUMBAI: World's largest insulin player Novo Nordisk today said it is launching long-lasting insulin injection Tresiba in the country soon.

"Tresiba (insulin degludec)-- a new basal insulin for adult patients with type 1 and type 2 diabetes to be available in India as a new treatment option. We are through with clinical trials and have received the necessary approvals. We hope to launch it by the end of this year," Novo Nordisk India Managing Director Melvin D'souza told reporters here.

Tresiba is a once-daily basal insulin with a duration of action beyond 42 hours, allowing for flexibility in day-to-day dosing time when needed, without compromising efficacy or risk of hypoglycaemia.

"In the current insulin treatments, people with diabetes are required to take their long-acting insulin at around the same time each day.

"However, the mode of action of insulin degludec ensures that, on occasions when this is not possible, people with diabetes can alter the time they take their insulin without compromising their diabetes control or putting themselves at increased risk of hypoglycaemia," Novo Nordisk India Clinical Medical and Regulatory Director Raman Shetty said.

Tresiba will be made available in prefilled pen with an easy touch button, enabling doses of up to 80 units in a single injection. The pricing will be announced at the time of the launch, D'souza said.

Novo Nordisk India has 15 per cent market share in the diabetes care segment. The company is hopeful of growing at 15 per cent per annum in the domestic market, D'souza said.

免责声明： 

      本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。 

      如有侵权，请联系我们删除